Judges Rule In Favor Of The Broad Institute For CRISPR Patent Case
Judges in U.S. Patent Trial and Appeal Board ruled that two CRISPR patents can coexist and come as a relief for Editas Medicine, the company that sells the DNA technology from Broad Institute .